Shanghai Shyndec Pharmaceutical (600420.SH) subsidiary obtains registration certificate for Levocarnitine Injection drug.

16:38 03/04/2026

Guoyao Xindu (600420.SH) announced that its controlling subsidiary, Guoyao Yixin Pharmaceutical Co., Ltd. (referred to as "Guoyao Yixin"), has received the Drug Registration Certificate for Levocarnitine Injection issued by the National Medical Products Administration. Levocarnitine Injection is used for a series of complications in chronic renal failure patients undergoing long-term hemodialysis due to secondary carnitine deficiency, including clinical manifestations such as cardiomyopathy, myopathy, arrhythmia, hyperlipidemia, hypotension, and muscle spasms during dialysis.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that its controlling subsidiary Guoyao Yixin Pharmaceutical Co., Ltd. (referred to as Guoyao Yixin) has received the "Drug Registration Certificate" for Levocarnitine Injection issued by the National Medical Products Administration. Levocarnitine Injection is suitable for chronic renal failure patients undergoing long-term hemodialysis who develop a series of complications due to secondary carnitine deficiency, with clinical manifestations such as cardiomyopathy, skeletal myopathy, arrhythmia, hyperlipidemia, low blood pressure, muscle spasms during dialysis, and other symptoms.

Industrial: Market fluctuations intensify. How are various types of funds moving?

Chairman Zheng Jiachun increased his holding of CHOW TAI FOOK (01929) by 30,000 shares at a price of approximately HK$10.76 per share.

Chairman Pan Binze increases his holdings in TEXWINCA HOLD (00321) by 2.76 million shares at a price of approximately 1.21 Hong Kong dollars per share.

Industrial: Market fluctuations intensify. How are various types of funds moving?

Chairman Zheng Jiachun increased his holding of CHOW TAI FOOK (01929) by 30,000 shares at a price of approximately HK$10.76 per share.

Chairman Pan Binze increases his holdings in TEXWINCA HOLD (00321) by 2.76 million shares at a price of approximately 1.21 Hong Kong dollars per share.